Probatebeta
Company

Hansa Biopharma

As of the edition of 20 October 2026, Hansa Biopharma runs 1 drug, 1 of them marketed; it is on route A at 0 targets and on route B at 4 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Marketed1
Total1

Marketed drugs and when their US protection ends

DrugUS protectionRoute B rows
Imlifidasenone listed4

A route B row is one company at one target.

Where it needs a new molecule

Route A at 0 targets, route B at 4 targets.

Three of its 4 rows, by target and route
TargetRoute
IGHG1 Immunoglobulin heavy constant gamma 1Route B
IGHG2 Immunoglobulin heavy constant gamma 2Route B
IGHG3 Immunoglobulin heavy constant gamma 3Route B

All 4 rows on route A or B

In the product

4 company-target rows on route A or B; 1 is not shown here, and no score is.

See all 4 targets where Hansa Biopharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.

Where its trials are

  • Pregnancy and women's health: 3 trials led
  • Urinary and reproductive: 3 trials led
  • Blood and lymph: 1 trials led

Targets where Hansa Biopharma has drugs

Other companies active in pregnancy and women's health